The treatment is based on a combination of two drugs currently used to treat psoriatic arthritis, Enbrel (etanercept) and Humira (adalimumab). The combination of these drugs is expected to provide longer-lasting relief with fewer side effects than Enbrel or Humira alone.
The treatment is expected to help patients improve their physical functioning and long-term health. This is due to providing soreness and pain relief, which will allow them to complete necessary routines related to hygiene, cooking, and other physical activities. Additionally, the treatment can help prevent joint deterioration, slow the rate of disease progression, and reduce the risk of disability.
The treatment should also reduce skin symptoms, such as psoriasis, itching, red patches, and scaly skin. This can help improve the patient’s quality of life and have an overall positive effect on their mental wellbeing.
The new psoriatic arthritis treatment is welcome news for those suffering from psoriatic arthritis and could provide a long-term solution. It is expected to increase patient satisfaction with treatment and reduce complaints related to the condition.
By 2022, the new psoriatic arthritis treatment is expected to be widely available, offering hope and much-needed relief to those living with psoriatic arthritis.
Article Created by A.I.